Immune cells known as T cells can destroy tumour cells, but their clinical use requires complex preparation and the cells can lose effectiveness over time. A new approach might improve the efficiency of T-cell therapy. See Letter p.113
This is a preview of subscription content, log in via an institution to check access.
Notes
References
Maus, M. V. & June, C. H. Clin. Cancer Res. 22, 1875–1884 (2016).
Eyquem, J. et al. Nature 543, 113–117 (2017).
Qasim, W. et al. Sci. Transl. Med. http://dx.doi.org/10.1126/scitranslmed.aaj2013 (2017).
Lombardo, A. et al. Nature Methods 8, 861–869 (2011).
Wang, J. et al. Nucleic Acids Res. 44, e30 (2016).
Sather, B. D. et al. Sci. Transl. Med. 7, 307ra156 (2015).
Frigault, M. J. et al. Cancer Immunol. Res. 4, 356–367 (2015).
Long, A. H. et al. Nature Med. 6, 581–590 (2015).
Wherry, E. J. & Kurachi, M. Nature Rev. Immunol. 15, 486–499 (2015).
Scholler, J. et al. Sci. Transl. Med. 4, 132ra53 (2012).
Tsai, S. Q. & Joung, J. K. Nature Rev. Genet. 17, 300–312 (2016).
Ren, J. et al. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-16-1300 (2017).
Author information
Authors and Affiliations
Corresponding author
Related links
Rights and permissions
About this article
Cite this article
Maus, M. T-cell tweaks to target tumours. Nature 543, 48–49 (2017). https://doi.org/10.1038/nature21506
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature21506
- Springer Nature Limited
This article is cited by
-
Programmable synthetic receptors: the next-generation of cell and gene therapies
Signal Transduction and Targeted Therapy (2024)
-
The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
Blood Cancer Journal (2023)
-
Mechanisms of resistance to CAR T cell therapy
Nature Reviews Clinical Oncology (2019)